<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03323801</url>
  </required_header>
  <id_info>
    <org_study_id>STUDY00001055</org_study_id>
    <nct_id>NCT03323801</nct_id>
  </id_info>
  <brief_title>RA-4: 13-cis Retinoic Acid for Treatment of Men With Azoospermia</brief_title>
  <official_title>A Pilot Trial of 13-cis Retinoic Acid (Isotretinoin) for the Treatment of Men With Azoospermia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Washington</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Men with infertility and normal hormone levels have few options for fertility treatment.
      Previous research suggests that men with infertility may have low levels of the active form
      of Vitamin A, called retinoic acid, in their testes. In a pilot study of 20 men with low
      numbers of sperm (&lt;10 million motile sperm), roughly half the men showed improvement in sperm
      production. Thus, we want to see if retinoic acid administration to men with azoospermia (no
      sperm present) can initiate sperm production.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Twenty men with infertility, aged 21 - 60, due to azoospermia (no apparent sperm in the
      ejaculate on two separate occasions) will be enrolled in a single-arm pilot trial of daily
      oral therapy of 20 mg twice daily of 13-cis retinoic acid for 32 weeks. The impact of
      treatment on the appearance of sperm in the ejaculate will be determined by monthly semen
      analyses.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 25, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2019</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>20 mg 13-cis retinoic acid twice daily (BID) with meals for 32 weeks</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total motile sperm</measure>
    <time_frame>up to 32 weeks</time_frame>
    <description>Total motile sperm in azoospermic men treated with 13-cis retinoic acid</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>13-cis retinoic acid serum level</measure>
    <time_frame>32 weeks</time_frame>
    <description>concentration level of 13-cis retinoic acid in the serum of treatment men</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serious and Non-Serious adverse effects</measure>
    <time_frame>32 weeks</time_frame>
    <description>Number of participants with Serious and Non-Serious Adverse effects associated with treatment with 13-cis retinoic acid</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>13-cis retinoic acid Seminal Plasma concentration</measure>
    <time_frame>up to 32 weeks</time_frame>
    <description>13-cis retinoic acid concentration in semen of treated men</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Male Infertility, Azoospermia</condition>
  <arm_group>
    <arm_group_label>13-cis retinoic acid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20 mg 13-cis retinoic acid twice daily (BID) with means for 32 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>13-cis retinoic acid</intervention_name>
    <description>Accutane is used for the treatment of severe acne</description>
    <arm_group_label>13-cis retinoic acid</arm_group_label>
    <other_name>Accutaine, Isotretinoin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: Infertile men with azoospermia on at least two semen analyses separated
        by at least one week, and no pregnancy with partner with normal cycles and normal
        hysterosalpinogogram despite &gt;1 year of unprotected intercourse.

        Exclusion Criteria: hypogonadotropic hypogonadism (that might respond to gonadotropin
        injections); use of anabolic steroids,illicit drugs, or consumption of more than 4
        alcoholic beverages daily; current therapy with retinoic acid (eg Accutane) or vitamin A-
        of use of isotretinoin within eight weeks of start of dosing;phenytoin, or medication
        containing tetracyline; personal history of serious psychiatric disorders, score of greater
        than 15 on the PHQ9 (mood) questionnaire; elevated serum serum triglycerides or other
        abnormal serum chemistry values; history of inflammatory bowel disease or bone disease; not
        living within catchment area; participation in another clinical trial
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John K Amory, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Washington</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Iris Nielsen</last_name>
    <phone>206-221-5473</phone>
    <email>nielseni@uw.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kathy Winter</last_name>
    <phone>206-616-0484</phone>
    <email>klwinter@uw.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Washington Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Iris Nielsen</last_name>
      <phone>206-221-5473</phone>
      <email>nielseni@uw.edu</email>
    </contact>
    <contact_backup>
      <last_name>Kathy Winter</last_name>
      <phone>206-616-0484</phone>
      <email>klwinter@uw.edu</email>
    </contact_backup>
    <investigator>
      <last_name>John K Amory, MD, MPH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.cdc.gov/nchs/fastats/fertile.htm</url>
    <description>Center for Disease Control, Infertility Facts, on June 3rd, 2013</description>
  </link>
  <reference>
    <citation>Jequier AM, Holmes SC. Primary testicular disease presenting as azoospermia or oligozoospermia in an infertility clinic. Br J Urol. 1993 Jun;71(6):731-5.</citation>
    <PMID>8102079</PMID>
  </reference>
  <reference>
    <citation>de Kretser DM. Male infertility. Lancet. 1997 Mar 15;349(9054):787-90. Review.</citation>
    <PMID>9074589</PMID>
  </reference>
  <reference>
    <citation>Schlegel PN. Nonobstructive azoospermia: a revolutionary surgical approach and results. Semin Reprod Med. 2009 Mar;27(2):165-70. doi: 10.1055/s-0029-1202305. Epub 2009 Feb 26. Review.</citation>
    <PMID>19247918</PMID>
  </reference>
  <reference>
    <citation>Napoli JL. Retinoic acid: its biosynthesis and metabolism. Prog Nucleic Acid Res Mol Biol. 1999;63:139-88. Review.</citation>
    <PMID>10506831</PMID>
  </reference>
  <reference>
    <citation>Doyle TJ, Braun KW, McLean DJ, Wright RW, Griswold MD, Kim KH. Potential functions of retinoic acid receptor A in Sertoli cells and germ cells during spermatogenesis. Ann N Y Acad Sci. 2007 Dec;1120:114-30. Epub 2007 Sep 28.</citation>
    <PMID>17905941</PMID>
  </reference>
  <reference>
    <citation>Koubova J, Menke DB, Zhou Q, Capel B, Griswold MD, Page DC. Retinoic acid regulates sex-specific timing of meiotic initiation in mice. Proc Natl Acad Sci U S A. 2006 Feb 21;103(8):2474-9. Epub 2006 Feb 6.</citation>
    <PMID>16461896</PMID>
  </reference>
  <reference>
    <citation>Anderson EL, Baltus AE, Roepers-Gajadien HL, Hassold TJ, de Rooij DG, van Pelt AM, Page DC. Stra8 and its inducer, retinoic acid, regulate meiotic initiation in both spermatogenesis and oogenesis in mice. Proc Natl Acad Sci U S A. 2008 Sep 30;105(39):14976-80. doi: 10.1073/pnas.0807297105. Epub 2008 Sep 17.</citation>
    <PMID>18799751</PMID>
  </reference>
  <reference>
    <citation>Chung SS, Wang X, Wolgemuth DJ. Expression of retinoic acid receptor alpha in the germline is essential for proper cellular association and spermiogenesis during spermatogenesis. Development. 2009 Jun;136(12):2091-100. doi: 10.1242/dev.020040.</citation>
    <PMID>19465599</PMID>
  </reference>
  <reference>
    <citation>Dufour JM, Kim KH. Cellular and subcellular localization of six retinoid receptors in rat testis during postnatal development: identification of potential heterodimeric receptors. Biol Reprod. 1999 Nov;61(5):1300-8.</citation>
    <PMID>10529278</PMID>
  </reference>
  <reference>
    <citation>Lohnes D, Kastner P, Dierich A, Mark M, LeMeur M, Chambon P. Function of retinoic acid receptor gamma in the mouse. Cell. 1993 May 21;73(4):643-58.</citation>
    <PMID>8388780</PMID>
  </reference>
  <reference>
    <citation>Lufkin T, Lohnes D, Mark M, Dierich A, Gorry P, Gaub MP, LeMeur M, Chambon P. High postnatal lethality and testis degeneration in retinoic acid receptor alpha mutant mice. Proc Natl Acad Sci U S A. 1993 Aug 1;90(15):7225-9.</citation>
    <PMID>8394014</PMID>
  </reference>
  <reference>
    <citation>Ghyselinck NB, Vernet N, Dennefeld C, Giese N, Nau H, Chambon P, Viville S, Mark M. Retinoids and spermatogenesis: lessons from mutant mice lacking the plasma retinol binding protein. Dev Dyn. 2006 Jun;235(6):1608-22.</citation>
    <PMID>16586441</PMID>
  </reference>
  <reference>
    <citation>Hoting VE, Schütte B, Schirren C. [Isotretinoin treatment of acne conglobata. Andrologic follow-up]. Fortschr Med. 1992 Aug 20;110(23):427-30. German.</citation>
    <PMID>1398387</PMID>
  </reference>
  <reference>
    <citation>Vogt HJ, Ewers R. [13-cis-Retinoic acid and spermatogenesis. Spermatological and impulse cytophotometric studies]. Hautarzt. 1985 May;36(5):281-6. German.</citation>
    <PMID>3159708</PMID>
  </reference>
  <reference>
    <citation>Török L, Kádár L, Kása M. Spermatological investigations in patients treated with etretinate and isotretinoin. Andrologia. 1987 Nov-Dec;19(6):629-33.</citation>
    <PMID>3481225</PMID>
  </reference>
  <reference>
    <citation>Nya-Ngatchou JJ, Arnold SL, Walsh TJ, Muller CH, Page ST, Isoherranen N, Amory JK. Intratesticular 13-cis retinoic acid is lower in men with abnormal semen analyses: a pilot study. Andrology. 2013 Mar;1(2):325-31. doi: 10.1111/j.2047-2927.2012.00033.x. Epub 2012 Nov 29.</citation>
    <PMID>23413144</PMID>
  </reference>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 24, 2017</study_first_submitted>
  <study_first_submitted_qc>October 24, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 27, 2017</study_first_posted>
  <last_update_submitted>October 24, 2017</last_update_submitted>
  <last_update_submitted_qc>October 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Washington</investigator_affiliation>
    <investigator_full_name>John Amory</investigator_full_name>
    <investigator_title>Professor, School of Medicine, General Internal Medicine</investigator_title>
  </responsible_party>
  <keyword>Infertility</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
    <mesh_term>Infertility, Male</mesh_term>
    <mesh_term>Azoospermia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tretinoin</mesh_term>
    <mesh_term>Isotretinoin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

